Committed to developing and commercializing new antibiotics to treat infectious diseases
Frazier Life Sciences originally invested in Zavante Therapeutics, a clinical late-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. In 2018, Zavante was acquired by Nabriva Therapeutics, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. In 2019, the U.S. FDA approved Nabriva’s oral and intravenous (IV) formulations of Xenleta (lefamulin) for the treatment of community-acquired bacterial pneumonia (CABP) in adults.